Cancer immunotherapy has transformed treatment landscapes for over 20 cancer types, but its success hinges on identifying the right candidates for therapy. Companion diagnostics are vital tools in this mission, leveraging biomarkers to guide personalized treatment decisions. They not only improve efficacy but also reduce unnecessary side effects by tailoring interventions to individual patients’ unique biological profiles.
Liquid biopsies, offering a non-invasive and comprehensive approach, hold immense promise as companion diagnostics for immunotherapies. Despite their potential, FDA-approved liquid biopsies supporting these therapies are scarce. Bridging this gap is crucial to advancing immunotherapy.
Immunotherapy Markers for Various Cancers :
Melanoma: BRAF, NRAS
NSCLC: EGFR, ALK, ROS1
SCLC: NSE
Kidney Cancer: VHL, MET
Bladder Cancer: FGFR3, TP53
Head & Neck Cancers: HPV, EGFR
Hodgkin Lymphoma: CD30, CD15
Non-Hodgkin Lymphoma: CD20, BCL2
Liver Cancer: AFP, HBV
Stomach Cancer: HER2, PD-L1
Colorectal Cancer: KRAS, MSI
Esophageal Cancer: HER2, TP53
Cervical Cancer: HPV
Endometrial Cancer: MSI, POLE
Ovarian Cancer: CA-125, BRCA1/BRCA2
Breast Cancer (HER2-positive): HER2, BRCA1/BRCA2
TNBC: BRCA1/BRCA2, PD-L1
Prostate Cancer: PSA, BRCA1/BRCA2
Pancreatic Cancer: KRAS, CDKN2A
Multiple Myeloma: BCMA, CD38
Merkel Cell Carcinoma: MCPyV
Urothelial Carcinoma: FGFR3, TP53
Thyroid Cancer: BRAF, RAS
At Celer Diagnostics, we are committed to developing innovative liquid biopsy solutions to provide precise, efficient, and accessible diagnostics. By advancing this technology, we aim to support healthcare providers in optimizing immunotherapy outcomes and ensuring that life-saving treatments reach the right patients.
With markers identified across cancers—such as EGFR in lung cancer, HER2 in breast and gastric cancers, and MSI in colorectal and endometrial cancers—there is a clear path forward for diagnostics development. At Celer Diagnostics, we’re not just envisioning the future; we’re building it. Together, we can redefine cancer care.
Explore more: https://www.linkedin.com/posts/celer-diagnostics_cancerresearch-immunotherapy-liquidbiopsy-activity-7261768093654228992-1nhI?utm_source=share&utm_medium=member_desktop
